Latest news and press releases about CNS Pharmaceuticals, Inc. (CNSP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer.
Price
| Price | $5.50 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.01 |
| EV / EBITDA | 0.70 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -204.25% |
| Return on Invested Capital | -92.94% |
| Return on Assets | -76.12% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CMND · ENSC · GRI · KTTA · NLSP · OGEN · SILO
Explore sector: Healthcare · Biotechnology
More sections of CNSP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks